An Innovative In Vivo Model for CAR-T-Cell Therapy Development: Efficacy Evaluation of CD19-Targeting CAR-T Cells on...

Area of Science:

• Immunology
• Oncology
• Developmental Biology

Background:

• Chimeric antigen receptor (CAR)-T-cell therapy shows promise for blood cancers.
• Rodent models are commonly used for preclinical CAR-T research but have limitations.
• There is a need for alternative in vivo models that are ethical, cost-effective, and efficient.

Purpose of the Study:

• To evaluate the efficacy of cluster-of-differentiation 19 (CD19)-targeting CAR-T cells in a chicken chorioallantoic membrane (CAM) assay.
• To assess the CAR-T cells' impact on tumor growth, metastasis, and angiogenesis.
• To investigate the interaction between CAR-T cells and the endogenous immune system within the CAM model.

Main Methods:

• Utilized the chicken chorioallantoic membrane (CAM) assay as an in vivo platform.
• Tested second-generation CAR constructs targeting CD19 against human lymphoma (Raji cell line).
• Analyzed tumor progression, metastasis, angiogenesis, and immune cell interactions.

Main Results:

• Demonstrated significant efficacy of CAR-T cells in inhibiting tumor growth, metastasis, and angiogenesis.
• Confirmed the CAR-T cells' effectiveness against CD19-positive lymphoma xenografts.
• Observed interactions between CAR-T cells and the host chicken immune system.

Conclusions:

• The chicken CAM assay is a viable and relevant in vivo model for preclinical CAR-T-cell therapy research.
• This assay adheres to the 3Rs principles (Replacement, Reduction, Refinement), offering a New Approach Methodology (NAM).
• The CAM assay provides a valuable platform for studying CAR-T cell efficacy and immune interactions in a cost-effective and timely manner.